LAZABEMIDE
|
- ₹9601.78 - ₹38017.4
- Product name: LAZABEMIDE
- CAS: 103878-84-8
- MF: C8H10ClN3O
- MW: 199.64
- EINECS:
- MDL Number:MFCD00865419
- Synonyms:LAZABEMIDE;LAZABEMIDE HYDROCHLORIDE;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;Ro-19-6327;2-PyridinecarboxaMide, N-(2-aMinoethyl)-5-chloro-;Ro 19-6327/000;Lazabemide hydrate;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate
2 prices
Selected condition：
Brand
- Sigma-Aldrich(India)
Package
- 10MG
- 50MG
- ManufacturerSigma-Aldrich(India)
- Product numberSML0042
- Product descriptionLazabemide hydrate ≥97% (HPLC)
- Packaging50MG
- Price₹38017.4
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberSML0042
- Product descriptionLazabemide hydrate ≥97% (HPLC)
- Packaging10MG
- Price₹9601.78
- Updated2022-06-14
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML0042 | Lazabemide hydrate ≥97% (HPLC) | 50MG | ₹38017.4 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML0042 | Lazabemide hydrate ≥97% (HPLC) | 10MG | ₹9601.78 | 2022-06-14 | Buy |
Properties
Boiling point :397.4±37.0 °C(Predicted)
Density :1.286±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :DMSO: ≥22mg/mL
pka :12.90±0.46(Predicted)
form :powder
color :white to tan
Density :1.286±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :DMSO: ≥22mg/mL
pka :12.90±0.46(Predicted)
form :powder
color :white to tan
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson’s disease. Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively. It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme. The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitro and ex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson’s disease.Related product price
- Lenalidomide
₹3583.08-27257.35 - Tetramethrin
₹5997.05-11258 - 5-CHLORO-2-FORMYLPYRIDINE
₹7300-17800
